Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.55
+0.06 (0.31%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Apellis Pharmaceuticals stock have an average target of 45.35, with a low estimate of 21 and a high estimate of 83. The average target predicts an increase of 158.48% from the current stock price of 17.55.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 7 | 8 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $24 → $21 | Hold | Maintains | $24 → $21 | +19.69% | Apr 21, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $30 → $31 | Hold | Maintains | $30 → $31 | +76.69% | Apr 2, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $50 → $54 | Buy | Maintains | $50 → $54 | +207.78% | Mar 4, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $26 → $25 | Hold | Maintains | $26 → $25 | +42.49% | Mar 3, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $32 | Hold | Maintains | $36 → $32 | +82.39% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
880.71M
from 781.37M
Increased by 12.71%
Revenue Next Year
1.07B
from 880.71M
Increased by 20.93%
EPS This Year
-1.03
from -1.60
EPS Next Year
0.23
from -1.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 989.0M | 1.3B | 1.9B | ||
| Avg | 880.7M | 1.1B | 1.3B | ||
| Low | 764.3M | 848.4M | 1.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.6% | 43.7% | 78.3% | ||
| Avg | 12.7% | 20.9% | 21.1% | ||
| Low | -2.2% | -3.7% | -4.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.19 | 1.92 | 3.81 | ||
| Avg | -1.03 | 0.23 | 1.48 | ||
| Low | -1.95 | -1.16 | 0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,540.7% | ||
| Avg | - | - | 537.7% | ||
| Low | - | - | 174.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.